Section of Cardiac Surgery, Division of Cardiac Sciences, Libin Cardiovascular Institute of Alberta, University of Calgary, Calgary, Alberta, Canada.
Section of Cardiac Surgery, Division of Cardiac Sciences, Libin Cardiovascular Institute of Alberta, University of Calgary, Calgary, Alberta, Canada.
Can J Cardiol. 2019 Feb;35(2):225-228. doi: 10.1016/j.cjca.2018.11.027. Epub 2018 Dec 4.
Aortic valve replacement (AVR) is the only definitive treatment for severe aortic stenosis. Options for valve replacement include surgical AVR (SAVR) and percutaneous transcatheter AVR. Although transcatheter AVR has recently been shown to be the optimal approach for high-risk patients, SAVR is the gold standard for patients with low and intermediate surgical risk. Advances in technique and innovations in rapid-deployment and sutureless valves have facilitated the development of a third alternative. Accumulating evidence suggests that minimally invasive SAVR can be performed as safely as conventional SAVR, and perhaps with less morbidity, allowing patients a quicker return to their productive lives. The following discussion outlines the surgical technique, patient selection and advances in valve design.
主动脉瓣置换术(AVR)是治疗严重主动脉瓣狭窄的唯一有效方法。瓣膜置换的选择包括外科主动脉瓣置换术(SAVR)和经皮经导管主动脉瓣置换术。尽管经导管 AVR 最近已被证明是高危患者的最佳治疗方法,但 SAVR 仍是低危和中危手术风险患者的金标准。技术的进步和快速部署以及无缝线瓣膜的创新促进了第三种选择的发展。越来越多的证据表明,微创 SAVR 可以像常规 SAVR 一样安全地进行,而且可能发病率更低,使患者更快地恢复到他们的生产生活中。下面的讨论概述了手术技术、患者选择和瓣膜设计的进展。